ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Other Events
Item8.01
| Other Events. |
On June5, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a
press release announcing updated results from the 20-mg expansion
cohort in the Companys ongoing Phase 1, multicenter,
dose-escalation study of its gene therapy candidate Ad-RTS-hIL-12
orally administered veledimex in patients with recurrent or
progressive glioblastoma. Such results will be presented at the
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
held June2-6, 2017 in Chicago, Illinois. A copy of the above
referenced press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits |
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 99.1 | Press release dated June 5, 2017. |
2
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
